An update on herpes virus infections in graft recipients

Nephrology Dialysis Transplantation

Volumn 18, Issue 9, 2003, Pages 1703-1706

  Ketteler, Markus ^a   Kunter, Uta ^a   Floege, Jürgen ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Human herpes virus; Immunosuppression; Renal transplantation; Viral infections

Indexed keywords

ACICLOVIR; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CIDOFOVIR; CYCLOPHOSPHAMIDE; DNA POLYMERASE; DOXORUBICIN; GABAPENTIN; GANCICLOVIR; GUANOSINE DERIVATIVE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; VALACICLOVIR; VALGANCICLOVIR; VINCRISTINE; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS DNA;

CHORIORETINITIS; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; EDITORIAL; ENTERITIS; EPSTEIN BARR VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCHEMISTRY; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; NONHUMAN; POLYMERASE CHAIN REACTION; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECIPIENT; SERODIAGNOSIS; TREATMENT PLANNING; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION;

HERPESVIRIDAE INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION;

EID: 0041883736     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg255     Document Type: Editorial

References (18)

1. Smith SR, Butterly DW, Alexander BD, Greenberg A. Viral infections after transplantation. Am J Kidney Dis 2001; 37: 659-676
2. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001; 12: 849-855
3. Halme L, Hockerstedt K, Salmela K, Lautenschlager I. CMV infection detected in the upper gastrointestinal tract after liver transplantation. Transplant Int 1998; 11 [Suppl 1]: S242-S244
4. Niedobitek G, Finn T, Herbst H et al. Detection of cytomegalovirus by in situ hybridisation and immunohistochemistry using new monoclonal antibody CCH2: a comparison of methods. J Clin Pathol 1988; 41: 1005-1009
5. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002; 72: 142-150
6. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35: 866-872
7. Martin DF, Sierra-Madero J, Walmsley S et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119-1126
8. Ketteler M, Preuschof L, Mertz A et al. Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant patient. Clin Nephrol 2000; 54: 418-424
9. Sester M, Sester U, Gartner B et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 1287-1294
10. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997; 76: 369-380
11. Penn I. De novo malignancies in pediatric organ transplant recipients. Pediatr Transplant 1998; 2: 56-63
12. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002; 17 [Suppl 4]: 31-33, 35-36
13. Wagner HJ, Wessel M, Jabs W et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001; 72: 1012-1019
14. Guba M, von Breitenbuch P, Steinhauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135
15. Majewski M, Korecka M, Kossev P et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97: 4285-4290
16. Green M, Michaels MG, Webber SA, Rowe D, Reyes J. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplant 1999; 3: 271-281
17. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002; 6: 280-287
18. Verschuuren EA, Stevens SJ, van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73: 100-104